Citations

Clear

493 citation(s) found for "Warren, C".

Glycoprotein 120 Binding to CXCR4 Causes p38-Dependent Primary T Cell Death That Is Facilitated by, but Does Not Require Cell-Associated CD4
Trushin, Sergey A., Algeciras-Schimnich, Alicia , Vlahakis, Stacey R., Bren, Gary D., Warren, Sarah, Schnepple, David, Badley, Andrew D. , Badley, Andrew D

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 178 | Issue: 8 | Pages: 4846-4853

10.4049/jimmunol.178.8.4846 | PMID 17404265 Get It

Abstract HIV-1 infection causes the depletion of host CD4 T cells through direct and indirect (bystander) mechanisms. Although HIV Env has been implicated in apoptosis of uninfected CD4 T cells via gp120 binding to either CD4 and/or the chemokine receptor 4 (CXCR4), conflicting data exist concerning the molecular mechanisms involved. Using primary human CD4 T cells, we demonstrate that gp120 binding to CD4 T cells activates proapoptotic p38, but does not activate antiapoptotic Akt. Because ligation of the CD4 receptor alone or the CXCR4 receptor alone causes p38 activation and apoptosis, we used the soluble inhibitors, soluble CD4 (sCD4) or AMD3100, to delineate the role of CD4 and CXCR4 receptors, respectively, in gp120-induced p38 activation and death. sCD4 alone augments gp120-induced death, suggesting that CXCR4 signaling is principally responsible. Supporting that model, AMD3100 reduces death caused by gp120 or by gp120/sCD4. Finally, prevention of gp120-CXCR4 interaction with 12G5 Abs blocks p38 activation and apoptosis, whereas inhibition of CD4-gp120 interaction with Leu-3a has no effect. Consequently, we conclude that gp120 interaction with CXCR4 is required for gp120 apoptotic effects in primary human T cells.
Stroke After Aortic Valve Surgery
Messé, Steven R. , Acker, Michael A., Fanning, Molly, Giovannetti, Tania , Ratcliffe, Sarah J. , Bilello, Michel , Szeto, Wilson Y. , Bavaria, Joseph E. , Hargrove, W. Clark , Mohler, Emile R., Floyd, Thomas F. , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Giovanetti, Tania, Matthai, William , Morris, Rohinton J., Pochettino, Alberto , Price, Catherine C. , Selnes, Ola A., Woo, Y. Joseph , Augostides, John G., Cheung, Albert T., Hanson, C. William , Kukafka, Jeremy D., Levy, Warren J., Mickler, Thomas, Milas, Bonnie L., Savino, Joseph S., Vernick, William J., Weiss, Stuart J., Kasner, Scott Eric , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Desai, Nimesh D. , Horák, Jiří , Kohl, Benjamin

Mayo Clinic

Circulation | April 2, 2014 | Volume: 129 | Issue: 22 | Pages: 2253-2261

10.1161/circulationaha.113.005084 | PMID 24690611 Get It

Background— The incidence and impact of clinical stroke and silent radiographic cerebral infarction complicating open surgical aortic valve replacement (AVR) are poorly characterized. Methods and Results— We performed a prospective cohort study of subjects ≥65 years of age who were undergoing AVR for calcific aortic stenosis. Subjects were evaluated by neurologists preoperatively and postoperatively and underwent postoperative magnetic resonance imaging. Over a 4-year period, 196 subjects were enrolled at 2 sites (mean age, 75.8±6.2 years; 36% women; 6% nonwhite). Clinical strokes were detected in 17%, transient ischemic attack in 2%, and in-hospital mortality was 5%. The frequency of stroke in the Society for Thoracic Surgery database in this cohort was 7%. Most strokes were mild; the median National Institutes of Health Stroke Scale was 3 (interquartile range, 1–9). Clinical stroke was associated with increased length of stay (median, 12 versus 10 days; P =0.02). Moderate or severe stroke (National Institutes of Health Stroke Scale ≥10) occurred in 8 (4%) and was strongly associated with in-hospital mortality (38% versus 4%; P =0.005). Of the 109 stroke-free subjects with postoperative magnetic resonance imaging, silent infarct was identified in 59 (54%). Silent infarct was not associated with in-hospital mortality or increased length of stay. Conclusions— Clinical stroke after AVR was more common than reported previously, more than double for this same cohort in the Society for Thoracic Surgery database, and silent cerebral infarctions were detected in more than half of the patients undergoing AVR. Clinical stroke complicating AVR is associated with increased length of stay and mortality.
Isolated Arthroscopic Rotator Interval Closure for Shoulder Instability
Krych, Aaron J. , Shindle, Michael K., Baran, Sean, Warren, Russell F. , Krych, Aaron J

Mayo Clinic

Arthroscopy Techniques | December 14, 2013 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.eats.2013.08.010 | PMID 24749020 Get It

Abstract We present our technique for isolated arthroscopic rotator interval closure in the treatment of mild symptomatic glenohumeral instability in the absence of a labral tear. A careful history, physical examination, and imaging help to identify a select subset of atraumatic instability patients who may benefit from this procedure, and diagnostic arthroscopy can provide further evidence. By use of a posterior viewing portal with anterior and anterolateral working portals, the anterior capsuloligamentous complex is mobilized, and the rotator interval is closed with carefully placed sutures to advance the capsule superiorly and provide tension through decreased capsular volume. Technique Video video See video under supplementary data.
P3–112: Patterns of regional brain atrophy and amyloid deposition in Alzheimer's disease
Duara, Ranjan , Barker, Warren , Shen, Qian , Greig‐Custo, Maria T., Varón, Daniel , Duara, Ranjan , Loewenstein, David , Murray, Melissa E. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1183 Get It

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Mahoney, Michelle R., Smyrk, Thomas C. , Thibodeau, Stephen N. , Warren, Robert S. , Nelson, Garth D. , Goldberg, Richard M. , Sinicrope, Frank A. , Bertagnolli, Monica M. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 10, 2013 | Volume: 31 | Issue: 29 | Pages: 3664-3672

10.1200/jco.2013.48.9591 | PMID 24019539 Get It

PurposeThe association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.Patients and MethodsResected, stage III colon carcinomas from patients (N = 2,686) randomly assigned to FOLFOX ± cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAFV600E(exon 15) and KRAS (codons 12 and 13). Association of biomarkers with disease-free survival (DFS) was determined using Cox models. A validation cohort (Cancer and Leukemia Group B 88903 trial) was used.ResultsdMMR was detected in 314 (12%) of 2,580 tumors, of which 49.3% and 10.6% had BRAFV600Eor KRAS mutations, respectively. MMR status was not prognostic overall (adjusted hazard ratio [HR], 0.82; 95% CI, 0.64 to 1.07; P = .14), yet significant interactions were found between MMR and primary tumor site (Pinteraction= .009) and lymph node category (N1 v N2; Pinteraction= .014). Favorable DFS was observed for dMMR versus proficient MMR proximal tumors (HR, 0.71; 95% CI, 0.53 to 0.94; P = .018) but not dMMR distal tumors (HR, 1.71; 95% CI, 0.99 to 2.95; P = .056), adjusting for mutations and covariates. Any survival benefit of dMMR was lost in N2 tumors. Mutations in BRAFV600E(HR, 1.37; 95% CI, 1.08 to 1.70; P = .009) or KRAS (HR, 1.44; 95% CI, 1.21 to 1.70; P < .001) were independently associated with worse DFS. The observed MMR by tumor site interaction was validated in an independent cohort of stage III colon cancers (Pinteraction= .037).ConclusionThe prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal tumors had favorable outcome, whereas distal or N2 tumors had poor outcome. BRAF or KRAS mutations were independently associated with adverse outcome.
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes
Malinge, Sébastien , Chlon, Timothy M. , Doré, Louis C. , Ketterling, Rhett P. , Tallman, Martin S. , Paietta, Elisabeth , Gamis, Alan S. , Weiss, Mitchell J. , Crispino, John D. , Figueroa, María E. , Chlon, Timothy M. , Taub, Jeffrey Warren , Chou, Stella T. , Crispino, John D , Ketterling, Rhett P

Mayo Clinic

Blood | August 27, 2013 | Volume: 122 | Issue: 14 | Pages: e33-e43

10.1182/blood-2013-05-503011 | PMID 23980066 Get It

Key PointsDNA methylation changes during the development of DS-AMKL occur in sequential waves of opposing losses and gains of methylation. Each wave of DNA methylation abnormalities targets specific gene networks that contribute to distinct biological features of the disease.
The Integration of Studio Cycling into a Worksite Stress Management Programme
Clark, Matthew M. , Soyring, Jason E., Jenkins, Sarah M. , Daniels, Denise C., Berkland, Bridget E., Werneburg, Brooke L., Hagen, Philip T., Warren, Beth A., Olsen, Kerry D., López-Jiménez, Francisco

Mayo Clinic

Stress and Health | July 30, 2013 | Volume: 30 | Issue: 2 | Pages: 166-176

10.1002/smi.2514 | PMID 23897838 Get It

AbstractHigh stress is a prevalent problem in the worksite. To reduce stress, improve productivity, reduce absenteeism, and lower healthcare costs, many companies offer exercise classes or stress management programmes. Although physical activity is an important component of stress management, few worksites have integrated physical activity into their comprehensive stress reduction programmes. The purpose of this single‐arm pilot project was to examine the potential effectiveness of an integrated exercise (studio cycling) and cognitive–behavioural stress management programme. Eighty‐four adults, 75% female, mostly aged 40+ years, participated in an integrated 12‐week cycling studio and cognitive–behavioural stress management programme. Participants experienced a significant and clinically meaningful reduction on the Perceived Stress Scale (p < 0.01), rating of current stress level and confidence to manage stress at the programme's end and at a 1‐month follow‐up. Participants also reported having significantly improved overall health, improved nutritional habits, higher physical activity level, greater confidence in their ability to follow a healthy diet, higher spiritual well‐being, improved sleep, receiving more support for maintaining healthy living and improved quality of life at the completion of the 12‐week programme and 1‐month follow‐up. These findings provide further support for an integrated exercise and stress management programme. Copyright © 2013 John Wiley & Sons, Ltd.
Uncommon Benign Breast Abnormalities in Adolescents
Warren, Rebekkah L., Warren, Rebekkah, Degnim, Amy C.

Mayo Clinic

Seminars in Plastic Surgery | May 23, 2013 | Volume: 27 | Issue: 01 | Pages: 026-028

10.1055/s-0033-1343993 | PMID 24872736 Get It

Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis
Tefferi, Ayalew , Paley, Carole, Wadleigh, Martha , Ritchie, Ellen K. , Snyder, David S., Begna, Kebede H. , Ganguly, Siddhartha , Ondovik, Michael S., Rine, Jessica, Bhalla, Kapil N. , DeAngelo, Daniel J. , Mesa, Ruben A. , Fiskus, Warren C.

Mayo Clinic

British Journal of Haematology | May 23, 2013 | Volume: 162 | Issue: 3 | Pages: 326-335

10.1111/bjh.12384 | PMID 23701016 Get It

SummaryMyelofibrosis (MF) is a Philadelphia chromosome–negative stem cell myeloproliferative neoplasm (MPN) associated with cytopenias, splenomegaly, constitutional symptoms, and poor prognosis. MF patients commonly express JAK2 V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF. This study evaluated panobinostat, a pan‐deacetylase inhibitor that depletes JAK2 V617F levels and JAK/STAT signalling in MPN cells, in patients with primary MF, post–essential thrombocythaemia MF, and post–polycythaemia vera MF. Patients received panobinostat 40 mg administered three times per week. Dose reductions were permitted for toxicities. The primary endpoint was response rate at 6 months using International Working Group for Myelofibrosis Research and Treatment (IWG‐MRT) consensus criteria. Analyses of peripheral blood cells from treated patients revealed that panobinostat inhibited JAK/STAT signalling, decreased inflammatory cytokine levels, and decreased JAK2 V617F allelic burden. However, panobinostat was poorly tolerated at the dose and schedule evaluated, and only 16 of 35 patients completed ≥2 cycles of treatment. One patient (3%) achieved an IWG‐MRT response. Common adverse events were thrombocytopenia (71·4%) and diarrhoea (80·0%). Although molecular correlative analyses suggested that panobinostat inhibits key intracellular targets, limited clinical activity was observed because of poor tolerance.
The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangiomyomatosis
STRIZHEVA, GALINA D., Carsillo, Thomas, Kruger, Warren D. , Sullivan, Eugene J., Ryu, Jay H. , HENSKE, ELIZABETH PETRI, Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 163 | Issue: 1 | Pages: 253-258

10.1164/ajrccm.163.1.2005004 | PMID 11208653 Get It

Abstract Lymphangiomyomatosis (LAM) is a progressive and often fatal interstitial lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. LAM is of unusual interest biologically because it affects almost exclusively young women. LAM can occur as an isolated disorder (sporadic LAM) or in association with tuberous sclerosis complex (TSC). Because only a minority of women with TSC develops symptomatic LAM, we hypothesized that a relationship might exist between the type of germline TSC1 or TSC2 gene mutation and the risk of developing LAM. We examined all 41 exons of the TSC2 gene and 21 coding exons of the TSC1 gene for mutations in a group of 14 women with both TSC and LAM using single-strand conformation polymorphism analysis. Seven mutations were found in TSC2 and one in TSC1. Of the seven patients with TSC2 mutations, two had the same in-frame exon 40 deletion and one had an exon 41 missense change. We conclude that germline mutations in the extreme carboxy-terminus of tuberin can result in LAM. Further studies will be required to determine whether mutations in exons 40 and 41 are associated with an increased incidence and/or severity of LAM in women with TSC.